Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
Cardiovascular

SS-31 + MOTS-c — Research Evidence Review: Mitochondrial Cardiovascular Mechanisms

Combination evidence review of SS-31 (elamipretide) and MOTS-c in cardiovascular research contexts. Mitochondrial inner-membrane stabilisation + AMPK / metabolic flexibility.

2 peptides 6-week study duration advanced evidence levelSave
Mitochondrial cardiolipin stabilisationCardiac ischaemia/reperfusion researchAMPK activationMetabolic flexibility

This is a research evidence review of the SS-31 + MOTS-c combination for mitochondrial and cardiovascular research contexts. It is not a protocol. Doses cited below are reported in study context only.

What the combination addresses

The combination targets two distinct axes of mitochondrial homeostasis:

  • SS-31 (elamipretide) — a four-amino-acid peptide that selectively binds cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for the function of the electron transport chain (particularly Complex IV) and for the structural integrity of cristae. In ischaemic, aged, or genetically-compromised mitochondria, cardiolipin oxidation drives loss of bioenergetic function; SS-31 stabilises cardiolipin and preserves cristae structure in published animal-model and in-vitro work.
  • MOTS-c — a 16-amino-acid mitochondrially-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. In rodent and cell-culture studies it activates AMPK, promotes metabolic flexibility (improved insulin sensitivity, fatty-acid oxidation), and modulates the mitochondrial unfolded-protein response.

See AMPK & mitochondrial mechanism map for the underlying pathway.

What has been directly studied?

No direct combination study has been published for SS-31 plus MOTS-c. The combination is inferred from monotherapy literature on each compound. See: direct combination evidence vs inferred stacks.

Monotherapy evidence

SS-31 (elamipretide)

The most clinically-developed mitochondrial peptide. Investigated in:

  • Primary mitochondrial myopathy (MMPOWER series) — mixed Phase II/III results on functional endpoints (6-minute walk distance, fatigue); biomarker improvements more consistent.
  • Barth syndrome (TAZPOWER trial) — cardiolipin abnormality-driven paediatric mitochondrial disorder.
  • Heart failure with reduced and preserved ejection fraction (Daubert 2017 and follow-on Phase II) — early signals; not yet definitive.
  • Ischaemia/reperfusion in renal and cardiac models — substantial preclinical evidence underpins the clinical programme.

MOTS-c

Predominantly preclinical. The headline finding (Lee 2015, Cell Metabolism) was that MOTS-c reduced high-fat-diet obesity and improved insulin sensitivity in mice via AMPK activation. Several follow-on papers in skeletal muscle, exercise mimetic contexts, and longevity models. Human data is limited to small-scale PK and exercise-response studies.

Why this combination is graded conservatively

  • No direct combination study has examined the pair together.
  • MOTS-c human evidence is sparse — translation from mouse to human is unproven.
  • SS-31 functional endpoints have been inconsistent in clinical trials despite favourable mechanism and biomarker results.

We grade this combination at Grade C in our A–X methodology: preclinical-dominant with limited human translation. See our evidence-level classifier for a step-by-step walk-through of how a grade like this is assigned.

Cardiovascular relevance

The cardiovascular framing for this combination rests on:

  • SS-31's direct cardiac trial programme (heart failure, ischaemia/ reperfusion).
  • MOTS-c's rodent metabolic-flexibility and cardiac-mitochondria literature.
  • The recognised role of mitochondrial dysfunction in heart failure, ischaemic cardiomyopathy, and ageing-related cardiac decline.

The mechanism is plausible. Translation to clinical cardiac outcomes in humans is not established.

Safety signals

  • SS-31 has a defined acute and chronic safety profile from the clinical programme — predominantly injection-site reactions, transient headache, mild GI symptoms.
  • MOTS-c human safety profile is poorly characterised; no signal in the small studies done.
  • The combination has no published safety data — additive or interactive safety cannot be inferred from monotherapy data.

Regulatory status

  • UK: both unapproved; no MHRA marketing authorisation. Research material is permissible for laboratory work only. See: UK regulation hub, what 'research use only' means.
  • Elsewhere: SS-31 (elamipretide) is investigational; MOTS-c is investigational with no marketed product.

Doses reported in published studies

The values below describe doses reported in research-context literature — typically rodent or in-vitro studies, occasionally early human trials. They are not recommendations, not a personal cycle, and not instructions for use. See our responsible information policy.

PeptideDoseFrequencyTimingCycle length
SS-31 (Elamipretide)5–10 mgDaily SCMorning4–6 weeks (study context)
MOTS-c5–10 mgEvery other day SCMorning4–6 weeks (study context)

Reported study-dose timeline

Week-by-week structure as it has been described in published research. Routes appear as recorded by study investigators — this is descriptive, not instructional.

PeptideWk 1Wk 2Wk 3Wk 4Wk 5Wk 6
SS-315 mg/d5 mg/d10 mg/d10 mg/d10 mg/d5 mg/d
MOTS-c5 mg EOD5 mg EOD10 mg EOD10 mg EOD10 mg EOD5 mg EOD

Routes recorded in studies: SC = subcutaneous · IM = intramuscular · IN = intranasal · Oral · Topical.

Safety signals & UK regulatory context

Frequently asked questions

Has this combination been directly studied?
No registered human RCT or peer-reviewed combination study has examined SS-31 plus MOTS-c together. The combination is inferred from monotherapy literature on each compound. See our explainer on direct vs inferred combinations.
What is the human evidence base for SS-31?
SS-31 (elamipretide) has been investigated in Phase II/III trials for primary mitochondrial myopathy (MMPOWER programme), Barth syndrome (TAZPOWER), heart failure with preserved ejection fraction, and ischaemia/reperfusion contexts. Results have been mixed on functional endpoints; biomarker improvements have been more consistent. As of mid-2026 it remains investigational.
What is the human evidence base for MOTS-c?
MOTS-c has limited published human data — primarily small-scale pharmacokinetic studies. The substantial preclinical literature is largely from the Cohen laboratory at USC. Translation to clinical cardiovascular or metabolic outcomes is not established.
Why is this graded conservatively despite SS-31 having human evidence?
SS-31 has human evidence as a monotherapy in narrow indications. The combination with MOTS-c has no direct study, and MOTS-c itself has minimal human data. Combination evidence inherits the weaker arm's grade.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Lee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015, 21(3), 443-54

Animal modelEvidence weight: low
Model
Mouse — high-fat-diet-induced obesity model and aged mice
Compound(s)
MOTS-c
Route in study
Intraperitoneal injection, daily
Outcome measured
Body weight, insulin sensitivity, AMPK pathway activation, hepatic glucose production
Main finding
MOTS-c reduced HFD-induced obesity, improved insulin sensitivity, and activated AMPK in skeletal muscle. Mouse model only.
Key limitation
Mouse model; high-dose IP administration not translatable to clinical scenarios. Cohen-lab originated and not extensively replicated in independent laboratories.
PubMed PMID:25738459

Reported in study context only — not a recommendation or protocol.

  1. Zheng H, Ou J, et al.. SS-31@Fer-1 alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes. Biomedicine & Pharmacotherapy. 2025;183 :117832 · PMID: 39848110
  2. Gong Z, Goetzman E, et al.. Cardio-protective role of Humanin in myocardial ischemia-reperfusion. Biochimica et Biophysica Acta. General Subjects. 2022;1866(2) :130066 · PMID: 34896254
  3. Lu P, Li X, et al.. The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates atherosclerosis. European Journal of Pharmacology. 2023;953 :175835 · PMID: 37290680
Published: 2026-05-21Last updated: 2026-05-21Last reviewed: 2026-05-21

Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading

Peptide

SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide

SS-31 (Elamipretide) is a D-amino-acid tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilising the electron transport chain and reducing pathological ROS.

Peptide

MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c

MOTS-c is a mitochondrial-derived peptide that activates AMPK, mimics exercise-induced gene expression, and declines with age — linking metabolic fitness to mitochondrial output.

Comparison

MOTS-c vs AOD-9604 — Mitochondrial vs GH-Fragment Fat-Loss Comparison

Research comparison of MOTS-c and AOD-9604: mechanisms, dosing, and evidence for fat-loss and metabolic research protocols.

Research

Triple Incretin Agonism — Retatrutide and the GLP-1 / GIP / Glucagon Evidence Base

Critical research-literacy review of the GLP-1 / GIP / glucagon triple-agonist class — receptor pharmacology, Phase II trial evidence for retatrutide, comparison with tirzepatide, and the UK regulatory framing.